Sanctuary Advisors LLC Makes New Investment in United Therapeutics Corporation $UTHR

Sanctuary Advisors LLC bought a new position in United Therapeutics Corporation (NASDAQ:UTHR) in the 2nd quarter, HoldingsChannel.com reports. The firm bought 1,695 shares of the biotechnology company’s stock, valued at approximately $918,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Meiji Yasuda Asset Management Co Ltd. bought a new position in shares of United Therapeutics during the second quarter valued at about $5,407,000. Bank of Nova Scotia bought a new stake in United Therapeutics in the 2nd quarter worth about $1,254,000. Kendall Capital Management bought a new stake in United Therapeutics in the 2nd quarter worth about $3,187,000. Hudson Portfolio Management LLC purchased a new stake in United Therapeutics in the 2nd quarter valued at about $740,000. Finally, Daiichi Life Insurance Co. Ltd. purchased a new stake in United Therapeutics in the 2nd quarter valued at about $4,485,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on UTHR shares. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Bank of America decreased their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Weiss Ratings upgraded United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, August 13th. JPMorgan Chase & Co. boosted their price objective on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Finally, Morgan Stanley set a $515.00 price objective on United Therapeutics in a research note on Thursday, August 6th. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $646.00.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $527.91 on Friday. The firm has a market cap of $22.64 billion, a price-to-earnings ratio of 18.89, a P/E/G ratio of 1.75 and a beta of 0.59. United Therapeutics Corporation has a 52 week low of $302.19 and a 52 week high of $609.35. The firm’s 50-day simple moving average is $530.89 and its two-hundred day simple moving average is $538.86.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. During the same period in the prior year, the firm earned $6.41 EPS. The company’s revenue was down 1.9% compared to the same quarter last year. Analysts forecast that United Therapeutics Corporation will post 26.33 earnings per share for the current year.

Insiders Place Their Bets

In other United Therapeutics news, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $523.14, for a total value of $4,342,062.00. Following the sale, the executive vice president directly owned 45,172 shares in the company, valued at $23,631,280.08. The trade was a 15.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $517.28, for a total value of $4,914,160.00. Following the transaction, the chief executive officer owned 324,443 shares of the company’s stock, valued at $167,827,875.04. The trade was a 2.84% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 424,075 shares of company stock valued at $227,336,485 over the last three months. Company insiders own 8.60% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.